RESUMEN
Relationship between various combinations of KIR ligands and HLA alleles have been studied in several diseases. The aim of this retrospective study was to estimate the frequency of HLA alleles and KIR ligands among acute myeloid leukemia patients and healthy controls in order to examine the possible association of HLA alleles and KIR ligands with AML. A total of 439 acute myeloid leukemia patients and 1317 unrelated, healthy ethnic Indian controls were included in the study. HLA typing was performed using PCR-SSP. KIR ligands were assigned by using the KIR ligand Calculator. The frequency of HLA alleles and KIR ligands in patients was then compared with the controls. As compared to controls, frequencies of HLA-A*03 and HLA-B*35 were increased in AML patients, whereas, that of HLA-C*03 was decreased. Frequencies of HLA-A*03 and HLA-C*15 were increased in male patients, however, no significant difference was observed in female patients as compared to controls. In the pediatric group, the frequencies of HLA-A*01 was decreased and that of HLA-A*03 and HLA-B*18 were increased, whereas, frequencies of HLA-B*13 was decreased and that of HLA-B*27 was increased in the adult patients. In the haplotype analysis, the frequency of HLA-A*24/B*35/DRB1*15 was increased in overall patients. In adult group, the frequency of HLA-A*01/B*44/DRB1*07 was increased in patients than in controls. No significant association was observed between KIR ligands and susceptibility/ protection to AML. Our results indicate that certain HLA alleles and haplotypes have presumptive positive or negative role in conferring protection/susceptibility to AML. Supplementary Information: The online version contains supplementary material available at 10.1007/s12288-022-01550-0.
RESUMEN
The most important strategy to ensure a safe and an adequate supply of blood and blood products is motivation, recruitment, selection and retention of voluntary non remunerated blood donors. With a view of the increased platelet necessity in our oncology setup, the first platelet donation drive in the city and to the best of our knowledge, in India was conducted by our hospital in November 2009. The aim was to identify target groups and expand our donor database. It was also essential that the donor's contribution is acknowledged and appropriately felicitated. A campaign called "Save a Life" was initiated and publicized locally. A core team consisting of Transfusion Medicine specialists, clinicians and an NGO (nongovernment organization) was formed. The best suitable date and venue were finalized for the platelet camp. The audience was addressed and willing donors were registered as volunteer platelet donors with our institute. In a span of 40 months, 15 platelet camps were organized in colleges, social organizations, and corporate offices. A total of 1035 donors were registered out of which, 382 (37%) donated platelets in our hospital. 125/382 (33.2%) donated Single Donor Platelets (SDP) more than once. The largest number of platelet donations by a single camp donor was 24 times. Due to multiple donations from donors, the SDP number was enhanced considerably and lead to addition of 699 SDP units to our inventory. The annual indoor and camp voluntary platelet donor numbers increased from 142 in 2006 to 631 in 2012 due to platelet drives. All platelet donations were altruistic as no incentives were offered to the donors. Ready availability of platelets and planning SDP inventory as per patient blood group requirements had a positive impact on clinical services.